Objectives : There are emerging evidences suggest that the development of tardive dyskinesia (TD) is related to the oxidative stress, excitotoxicity, and immune activation. The purpose of this study is to investigate whether single-nucleotide polymorphisms (SNPs) of tumor necrosis factor (TNF)-α genes are associated with the susceptibility of TD and schizophrenia. Methods : We investigated two hundred and eighty Korean schizophrenic patients. The schizophrenic participants consisted of patients with (n=105) and without (n=175) TD who were matched for antipsychotic drug exposure and other relevant variables. The TNF-α gene -308G/A SNPs were analyzed by polymerase chain reaction (PCR)-based methods. Results : The frequencies of genotype (χ 2 =0.33, p=0.848) of the TNF-α gene -308 G/A SNP did not differ significantly between schizophrenic patients with and without TD. The difference of allele frequencies (χ 2 =0.28, p=0.594) of the TNF-α gene between the schizophrenic patients with and without TD were not significant. Conclusion : These results suggest that the TNF-α gene -308 G/A SNPs are not associated with TD and schizophrenia in a Korean population. Further association studies of TD with other candidate genes for cytokines would help us understand the pathophysiological mechanisms of TD. (Korean J Schizophr Res 2013;16:38-42) REFERENCES 1) Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-120. 2) Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York: Guilford Press;1982. p.363. 3) Khot V, Egan M, Hyde T, Wyatt R. Neuroleptics and classic tardive dyskinesia. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. New York: Futura;1992. p.121-166. 4) Miller CH, Simioni I, Oberbauer H, Schwitzer J, Barnas C, Kulhanek F, et al. Tardive dyskinesia prevalence rates during a ten-year followup. J Nerv Ment Dis 1995;183:404-407. 5) Sweet RA, Mulsant BH, Gupta B, Rifai AH, Pasternak RE, McEachran A, et al. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 1995;52:478-486. 6) Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133-139 7) Rosengarten H, Schweitzer JW, Friedhoff AJ. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 1994;49:663-667.

